We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Allergan announced Tuesday that the FDA has issued a complete response letter regarding its marketing application for Esmya (ulipristal) for the treatment of abnormal uterine bleeding in women with uterine fibroids. According to Allergan......